NCT03698994 2025-12-03Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting20 enrolled 9 charts
NCT03520842 2023-08-01Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung CancerStanford UniversityPhase 2 Completed22 enrolled 20 charts